AbbVie Declares Quarterly Dividend
5 september, 2025
AbbVie Declares Quarterly Dividend
PR Newswire
NORTH CHICAGO, Ill., Sept. 5, 2025
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
The cash dividend is payable November 14, 2025 , to stockholders of record at the close of business on October 15, 2025 .
Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube.
Media: Gabby Tarbert (224) 244-0111 | Investors: Liz Shea |
SOURCE AbbVie
AbbVie Declares Quarterly Dividend
5 september, 2025
AbbVie Declares Quarterly Dividend
PR Newswire
NORTH CHICAGO, Ill., Sept. 5, 2025
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
The cash dividend is payable November 14, 2025 , to stockholders of record at the close of business on October 15, 2025 .
Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube.
Media: Gabby Tarbert (224) 244-0111 | Investors: Liz Shea |
SOURCE AbbVie
Krypto
Analys
Ståltullar
Rapportperioden
Utdelning
Lock-up
Krypto
Analys
Ståltullar
Rapportperioden
Utdelning
Lock-up
Marknadsöversikt
1 DAG %
Senast
1 mån
